-

CEO of Midwest Transplant Network Jan Finn Joins MTF Biologics Board of Directors

Finn will bring 30 years of organ procurement experience to the MTF Biologics Board

EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing science, has announced that Jan Finn, President and Chief Executive Officer of the Midwest Transplant Network, has joined the organization’s Board of Directors.

“MTF Biologics is excited to welcome Jan onto our Board of Directors,” said Joe Yaccarino, President and Chief Executive Officer at MTF. “Jan brings nearly 30 years of organ procurement experience to the MTF Biologics Board. She is extremely passionate about our work to provide high-quality tissue grafts from donated human tissue and understands the positive impact that the gift of donation has on the lives of both recipients and donor families. We know that she will be an invaluable asset to our MTF team.”

As the President/Chief Executive Officer for Midwest Transplant Network (MTN), Ms. Finn is responsible for overseeing the executive leadership of a team that directs all organ and tissue donation operations in Kansas and Western Missouri. Under her leadership, MTN increased its donation rates and recovery of organs and tissues to record levels. MTN ranks in the top quartile nationally among other OPOs.

Ms. Finn currently serves on the Missouri Governor’s Advisory Council on Organ and Tissue Donation, the Legislative and Regulatory Affairs Committee for the Association of Organ Procurement Organizations (AOPO) and as a board member for the Gift of Life Foundation and the National Organ Donation Alliance. She is a past President of the North American Transplant Coordinators Organization (NATCO) and achieved certification from the American Board for Transplant Coordination as a Certified Procurement Transplant Coordinator (CPTC).

Ms. Finn began her career at St. John’s Regional Medical Center in Joplin, MO, working for 13 years as a Registered Nurse primarily in critical care. She holds undergraduate degrees from Missouri Southern State University and Pittsburg State University, as well as Master’s in Science from the University of Kansas. She was a member of the Sigma Theta Tau Nursing Honor Society and was credentialed as a CCRN by the American Association of Critical Care Nurses.

“I am delighted to join my friends at MTF Biologics as a member of their Board of Directors,” said Ms. Finn. “MTF Biologics remains a global leader in tissue and organ transplantation, and I look forward to working with the Board to help further MTF’s legacy of honoring donors and saving and healing lives.”

ABOUT MTF BIOLOGICS

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. They provide unmatched service, resources, and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists.

The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe. For more information, visit www.mtfbiologics.org.

Contacts

Kate Raley, 615-610-0202 or kate.raley@finnpartners.com

MTF Biologics


Release Versions

Contacts

Kate Raley, 615-610-0202 or kate.raley@finnpartners.com

More News From MTF Biologics

MTF Biologics and Kolosis BIO Launch Two New Allografts to Advance Cardiac Surgery

EDISON, N.J. & SALT LAKE CITY--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of biologic solutions, today announced they have partnered to bring two innovative allograft tissues to cardiac surgeons: ATLAS™ Sternal Repair Matrix for sternal fusion and IKON™ Allograft Surgical Matrix for soft tissue repair in high-risk patients. These hi...

MTF Biologics Completes First Implantation of FlexHD® Pliable in Milestone Breast Reconstruction Clinical Trial

EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, today announced the successful implantation of FlexHD® Pliable in the first patient enrolled in its Investigational Device Exemption (IDE) clinical study for pre-pectoral breast reconstruction. This milestone pivotal study (SHAPE) aims to evaluate the safety and effectiveness of FlexHD® Pliable in implant-based breast rec...

MTF Biologics Appoints Donald Hackbarth and Sharon Gabrielson to Key Leadership Roles on Board of Directors

EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, has appointed two new key leaders to its board of directors. Dr. Donald Hackbarth has been named Chair of the Board of Directors, succeeding Dr. William Tomford after his dedicated tenure, and Sharon Gabrielson, BSN, MBA, has been named Vice Chair of the Board. These changes mark a new chapter in the organization’s leader...
Back to Newsroom